Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBMI in PSP and MSA
NCT04184063Phase 2Completed
- Sponsor
- EmeraMed
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emeramide in progressive supranuclear palsy (PSP), multiple system atrophy (MSA), sponsored by EmeraMed. Started Sep 2019; status: completed.
02
Drugs
emeramide
03
Conditions
progressive supranuclear palsy (PSP)multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT04184063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184063.